Pfizer’s COVID-19 vaccine trial data shows long-term efficacy

Pfizer’s COVID-19 vaccine
Pfizer said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.

The vaccine was authorized for emergency use in people aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August.



from latest-news - SUCH TV https://ift.tt/3FFnxyl

Comments

Popular posts from this blog

Dollar waits on CPI, yuan bounces back from policy knock

President Ashraf Ghani launches Afghanistan's coronavirus vaccine campaign

Biden urges calm in first call with Palestinian President Mahmoud Abbas

Sindh govt seeks army's help in implementation of coronavirus SOPs

Low payments by fed govt hampered development in Sindh, CM Murad tells Bilawal Bhutto

Biden and Xi discuss avoiding conflict in first phone call in 7 months

Biden sends Ramazan greetings, says his govt will protect rights and safety of all people

Shahbaz Sharif terms mini-budget a death knell for Pakistan

Taliban declare war in Afghanistan over, call for peaceful relations with world

North Korea imported Chinese masks before declaring Covid victory